ClinicalTrials.gov
ClinicalTrials.gov Menu

Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01645241
Recruitment Status : Completed
First Posted : July 20, 2012
Last Update Posted : October 27, 2014
Sponsor:
Collaborators:
FUNDACION DEXEUS SALUT DE LA DONA
Ayudas Merck Serono de Investigación 2012
Information provided by:
Institut Universitari Dexeus

Brief Summary:
The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes donors . This study will be performed in egg recipients and donors but this type of treatment is meant to be implemented in fertility preservation patients

Condition or disease Intervention/treatment Phase
INFERTILITY Fertility Preservation Ovulation Induction Vitrification Oocyte Donation Drug: gonadotropins plus GnRH antagonists Drug: ganirelix Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
Study Start Date : July 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Lutheal phase ovarian stimulation
Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
Drug: gonadotropins plus GnRH antagonists
Other Name: Ovarian stimulation
Drug: ganirelix
Other Name: the investigators will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix



Primary Outcome Measures :
  1. Pregnancy rate [ Time Frame: six weeks after transfer procedure ]

Secondary Outcome Measures :
  1. Number of Mature oocytes [ Time Frame: Day of oocyte retrieval ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • premenopausal women, 18-35 years old, FSH levels < 10 mIU/ml; AFC> 10
  • regular cycles
  • BMI < 28
  • signed informed consent

Recipients:

  • Infertile women eligible for oocytes donation
  • BMI < 35
  • Signed informed consent form

Exclusion Criteria:

-Polycystic ovarian syndrome, gonadotropins allergy

Recipients:

  • Women eligible for oocytes donation
  • BMI >35
  • Uncontrolled Endocrine Pathology

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01645241


Locations
Spain
Departamento de Obstetricia Ginecologia y Reproducción. Institut Universitari Dexeus
Barcelona, Spain, 08037
Sponsors and Collaborators
Institut Universitari Dexeus
FUNDACION DEXEUS SALUT DE LA DONA
Ayudas Merck Serono de Investigación 2012
Investigators
Principal Investigator: Francisca Martínez, PhD Fundación Dexeus Salut de la Dona

Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT01645241     History of Changes
Other Study ID Numbers: DEX005
First Posted: July 20, 2012    Key Record Dates
Last Update Posted: October 27, 2014
Last Verified: March 2013

Keywords provided by Institut Universitari Dexeus:
Ovarian stimulation
Luteal phase
Egg donors
Fertility preservation

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Ganirelix
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs